← 產業報告目錄
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Size, Share & Trends Analysis Report By Drug Class (Bronchodilators, Combination, Corticosteroids, Phosphodiesterase), By Type (Chronic Bronchitis, Emphysema), By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-13頁數 179報告編號 INSIGHTACE-51595ea771
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 19.49 Bn as of 2023, the global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market is poised to climb to USD 33.61 Bn by 2031, reflecting a compound annual growth rate of 7.20% over the 2024–2031 period.
The Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials sector involves key industry insights & findings from the report:
The expanding government initiatives and investments for research and developments drive the market growth. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is fueled by expanding requirement advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Snapshot
Chapter 4. Global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drug Class:
5.2.1. Bronchodilators
5.2.2. Combination
5.2.3. Corticosteroids
5.2.4. Phosphodiesterase
Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis
6.1. By Type & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type:
6.2.1. Chronic Bronchitis
6.2.2. Emphysema
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts By Drug Class, 2024-2031
8.1.2. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts By Type, 2024-2031
8.1.3. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2024-2031
8.1.4. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, 2024-2031
8.2.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, 2024-2031
8.2.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel, 2024-2031
8.2.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, 2024-2031
8.3.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, 2024-2031
8.3.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel, 2024-2031
8.3.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, (US$ Million) 2024-2031
8.4.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, (US$ Million) 2024-2031
8.4.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel (US$ Million) 2024-2031
8.4.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, (US$ Million) 2024-2031
8.5.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, (US$ Million) 2024-2031
8.5.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2024-2031
8.5.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. AstraZeneca,
9.2.2. Boehringer Ingelheim International GmbH,
9.2.3. CHIESI Pharmaceutics S.p.A.,
9.2.4. Glaxo SmithKline plc,
9.2.5. Mylan N.V.,
9.2.6. Novartis AG,
9.2.7. Sunovion Pharmaceuticals, Inc.
9.2.8. (Sumitomo Dainippon Pharma Co., Ltd.,
9.2.9. Teva Pharmaceutical Industries Ltd,
9.2.10. Pfizer Inc.,
9.2.11. Almirall,
9.2.12. Astellas Pharma
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們